NCT05529589 is a clinical trial in Macular Edema Due to Diabetes Mellitus, sponsored by Second Affiliated Hospital, School of Medicine, Zhejiang University.

Who is sponsoring NCT05529589?

NCT05529589 is sponsored by Second Affiliated Hospital, School of Medicine, Zhejiang University.

What condition does NCT05529589 study?

NCT05529589 studies Macular Edema Due to Diabetes Mellitus, Vitreous Hemorrhage.

Is NCT05529589 still recruiting?

NCT05529589 is currently status unknown. Last updated 6 February 2023.

Last reviewed 2023-02-06 · How we verify

NCT05529589

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Comparison of Restoration in Vitreous Hemorrhage Patients With DME After or Not Removing Inner Limiting Membrane

Status unknown Last updated 6 February 2023

What this trial tests

trial in Macular Edema Due to Diabetes Mellitus in 120 participants. Status unknown.

Timeline

10 February 2023

Primary endpoint
30 October 2023

30 October 2023

Quick facts

Lead sponsor	Second Affiliated Hospital, School of Medicine, Zhejiang University
Status	Status unknown
Study type	OBSERVATIONAL
Enrollment	120
Start date	10 February 2023
Primary completion	30 October 2023
Estimated completion	30 October 2023
Sites	1 location across China

Conditions studied

Macular Edema Due to Diabetes Mellitus — all drugs for Macular Edema Due to Diabetes Mellitus →
Vitreous Hemorrhage — all drugs for Vitreous Hemorrhage →

Sponsor

Second Affiliated Hospital, School of Medicine, Zhejiang University

Who can join

Adults 18 to 80, any sex, with Macular Edema Due to Diabetes Mellitus or Vitreous Hemorrhage. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

This study is conducted to compare the anti-VEGF effect and visual function in vitreous hemorrhage patients with diabetic macular edema after pars plana vitrectomy with inner limiting membrane peeling or not

Publications & conference data

No peer-reviewed publications indexed yet for this trial.

Verify or expand the search:

Other Second Affiliated Hospital, School of Medicine, Zhejiang University trials

Trials by the same sponsor.

NCT07445152 — Research on Construction and Verification of Multimodal Medical Imaging Large Model · not yet recruiting
NCT06775665 — A Real-World Study on Hypertrophic Cardiomyopathy in Chinese Population · not yet recruiting
NCT07533422 — Rescue Reatment of Helicobacter Pylori Based on Fecal Antimicrobial Resistance Gene Testing · NA · not yet recruiting
NCT07487285 — A Non-inferiority Study of Laser Combined With Ultrasonic Debridement Therapy (LCUDT) Versus Manual Combined With Ultras · NA · not yet recruiting
NCT07505186 — Camrelizumab, Chemotherapy and Ivarmacitinib in Patients With Resectable Esophageal Squamous Cell Carcinoma · Phase 2 · not yet recruiting

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT05529589 (US National Library of Medicine, public domain)
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by Second Affiliated Hospital, School of Medicine, Zhejiang University
Last refreshed: 6 February 2023

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT05529589.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing